172 related articles for article (PubMed ID: 34876272)
61. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
62. How I treat adverse effects of CAR-T cell therapy.
Yáñez L; Alarcón A; Sánchez-Escamilla M; Perales MA
ESMO Open; 2020 Aug; 4(Suppl 4):e000746. PubMed ID: 32839196
[TBL] [Abstract][Full Text] [Related]
63. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
64. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
65. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
66. [Not Available].
Le Bourgeois A
Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
[TBL] [Abstract][Full Text] [Related]
67. [Vaccination].
Graubner UB; Liese J; Belohradsky BH
Klin Padiatr; 2001 Sep; 213 Suppl 1():A77-83. PubMed ID: 11577366
[TBL] [Abstract][Full Text] [Related]
68. [Infections following bone marrow transplantation].
Ljungman P; Andersson J; Sparrelid E
Nord Med; 1995; 110(12):320-1. PubMed ID: 8524635
[TBL] [Abstract][Full Text] [Related]
69. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
70. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
71. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
72. Infections in allogeneic bone marrow transplant recipients.
Wingard JR
Semin Oncol; 1993 Oct; 20(5 Suppl 6):80-7. PubMed ID: 8211220
[TBL] [Abstract][Full Text] [Related]
73. [Renal failure after allogeneic hematopoietic stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].
Detrait M; de Berranger E; Dulery R; Ménard AL; Thépot S; Toprak SK; Turlure P; Yakoub-Agha I; Guillaume T
Bull Cancer; 2020 Jan; 107(1S):S28-S35. PubMed ID: 31303250
[TBL] [Abstract][Full Text] [Related]
74. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
75. Infectious complications of human bone marrow transplantation.
Winston DJ; Gale RP; Meyer DV; Young LS
Medicine (Baltimore); 1979 Jan; 58(1):1-31. PubMed ID: 368507
[TBL] [Abstract][Full Text] [Related]
76. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.
Akhoundi M; Mohammadi M; Sahraei SS; Sheykhhasan M; Fayazi N
Cell Oncol (Dordr); 2021 Jun; 44(3):495-523. PubMed ID: 33759063
[TBL] [Abstract][Full Text] [Related]
77. How close are we to CAR T-cell therapy for AML?
Gill SI
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
[TBL] [Abstract][Full Text] [Related]
78. [Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Brissot E; Alsuliman T; Beauvais D; Bonnin A; Mear JB; Souchet L; Villate A; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2020 Jan; 107(1S):S1-S6. PubMed ID: 31627903
[TBL] [Abstract][Full Text] [Related]
79. [Role of advanced practice nurse within a cellular therapy unit: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC)].
Jezequel T; Cheron N; Ajazi Hub R; Brouillat C; Colonnese E; Desmedt C; Evard S; Hie S; Mourrut C; Vallade D; Bouhier I; Chauvel C; Gandemer V; Mercier L; Yakoub-Agha I
Bull Cancer; 2024 Feb; 111(2S):S50-S66. PubMed ID: 36797127
[TBL] [Abstract][Full Text] [Related]
80. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
Dudley CV; Baer B; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
